A rat extremity soft tissue sarcoma model for the study of systemic treatment with Stealth® liposome-encapsulated tumor necrosis factor-α and cytotoxic agents

Advanced Drug Delivery Reviews

Volumn 24, Issue 2-3, 1997, Pages 245-256

  Ten Hagen, Timo L M ^a   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

liposomal antitumor agents; liposomal TNF ; solid tumors; systemic treatment

Indexed keywords

CONTROLLED DRUG DELIVERY; DRUG DOSAGE; DRUG INTERACTIONS; DRUG PRODUCTS; ENCAPSULATION; IMMUNOLOGY; LIPIDS; MATHEMATICAL MODELS; PATIENT TREATMENT; PHARMACOKINETICS;

ISOLATED LIMB PERFUSION; LIPOSOMAL ANTITUMOR AGENTS; SOFT TISSUE SARCOMA MODEL; SOLID TUMORS; SYSTEMIC TREATMENT; TUMOR NECROSIS FACTOR ALPHA;

DRUG THERAPY;

CYTOTOXIC AGENT; DOXORUBICIN; GAMMA INTERFERON; LIPOSOME; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; CIRCULATION TIME; CLINICAL TRIAL; CONFERENCE PAPER; ENCAPSULATION; FEVER; HUMAN; HYPOTENSION; IMMUNITY; LEUKOPENIA; LIMB PERFUSION; LIMB TUMOR; LIVER TOXICITY; MELANOMA; METASTASIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 0343852342     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00465-6     Document Type: Conference Paper

References (88)

1. Dvorak, H.F., Brown, L.F., Detmat, M. and Dvorak, A.M. (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146, 1029-1039.
2. Jain, R.K. (1987) Transport of molecules across tumor vasculture. Cancer Metastasis Rev. 47, 559-593.
3. Yuan, F., Leunig, M., Huang, S.K., Berk, D.A., Papahadjopoulos, D. and Jain, R.K. (1994) Microvasculature permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54, 3352-3356.
4. Carswell, E.A., Old, L.J., Kassel, R.L., Green, S., Fiore, N. and Wlliamson, B. (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666-3670.
5. Tartaglia, L.A., Weber, R.F., Figari, I.S., Reynolds, C., Palladino, M.A. and Goeddel, D.V. (1991) The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA 88, 9292-9296.
6. Gatanaga, T., Noguchi, K., Tanabe, Y., Inagawa, H., Soma, G.-I. and Mizuno, D. (1989) Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with Less toxicity than conventional rTNF-α in vivo. J. Biol. Reponse Modif. 8, 278-286.
7. Kuroda, K., Miyata, K., Shikama, H., Kawagoe, T., Nishimura, K., Takeda, K., Sakae, N., Sakae, N. and Kato, M. (1995) Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice. Int. J. Cancer 63, 152-157.
8. AM2, in an anesthetized dog model. J. Immunther. 17, 19-29.
9. Miyata, K., Kato, M., Nishimura, K., Sakae, N., Kawagoe, K., Nishikawa, T., Kuroda, K., Yamaguchi, K., Aoyama, Y., Mitsuishi, Y. and Yamada, N. (1992) A YIGSR-containing novel mutein without the detrimental enhancing effect of human TNF-α of enhancing experimental pulmonary metastasis. Clin. Exp. Metastasis 10, 267-272.
10. Shikama, H., Miyata, K., Sakae, N., Muitsuishi, Y., Nishimura, K., Kuroda, K. and Kato, M. (1995) Novel mutein of tumor necrosis factor (F4614) with reduced hypotensive effect. J. Interf. Cytok. Res. 15, 677-684.
11. Tavernier, J., Fransen, L., Marmenout, A., van der Heyden, J., Mueller, R., Ruysscheart, M-R, van Vliet, A., Bauvdem, R. and Fiers, W. (1987) Isolation and expression of the genes coding for mouse and human tumor necrosis factor (TNF) and biological properties of recombinant TNF. In: D.R. Webb, and D.V. Goeddel (Eds.), Lymphokines. Vol 13, Academic Press, New York, pp. 181-198.
12. Jacobsen, S.E.W., Ruscetti, F.W, Dubois, C.M. and Keller, J.R. 1992. Tumor necrosis factor a directly and indirectly regulates hematopoietic progenitor cell proliferation: role of colony-stimulating factor receptor modulation. J. Exp. Med. 175, 1759-1772.
13. Nawroth, P.P. and Stern, D.M. (1986) Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 163, 740-745.
14. Asher, A.L., Mule, J.J., Reichert, C.M., Shiloni, E. and Rosenberg, S.A. (1987) Studies of the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J. Immunol. 138, 963-974.
15. Blick, M.B., Sherwin, S.A., Rosenblum, M. et al. (1987) A phase I trial of recombinant human tumor necrosis factor in cancer patients. Cancer Res. 47, 2986-2989.
16. Creaven, P.J., Plager, J.E., Dupere, S. et al., (1987) Phase I trial of recombinant human tumor necrosis factor. Cancer Chemother. Pharmacol. 20, 137-144.
17. Spriggs, D.R., Sherman, M.L., Michie, H. et al. (1988) Recombinant human tumor necrosis factor administered as a 24 h intravenous infusion. A phase I and pharmacologic study. J. Natl. Cancer Inst. 80, 1039-1044.
18. Sugarman, B.J., Aggarwal, B.B., Hass, P.E. et al. (1985) Recombinant tumor necrosis factor-αlpha: effects on proliferation of normal and transformed cells in vitro. Science 230, 943-945.
19. Carswell, E.A., Old, L.J., Kassel, R.L. et al. (1975) An endotoxin induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666-3370.
20. Balkwill, F.R., Lee, A., Aldham, G. et al. (1986) Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res. 46, 3990-3993.
21. Manusama, E.R., Nooijen, P.T.G.A., Stavast, J., Durante, N.M.C., Marquet, R.L. and Eggermont, A.M.M. (1996) Synergistic antimour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat. Br. J. Surg. 83, 551-555.
22. Manda, T., Nishigaki, F., Mukumoto, S., Masuda, K., Nakamura, T. and Shimomura, K. (1990) The efficacy of combined treatment with recombinant human tumor necrosis factor-α and 5-fluorouracil is dependent on the development of capillaries in tumor. Eur. J. Cancer 26, 93-99.
23. Mule, J.J., Asher, A., McIntosh, J. et al. (1988) Antitumor effect of recombinant tumor necrosis factor-α against murine sarcomas at visceral sites: tumor size influences the response to therapy. Cancer Immunol. Immunother. 26, 202-208.
24. Weidner, N. and Folkman, J. (1996) Tumor vascularity as a prognostic factor in cancer. In: V.T. DeVita, S. Hellman and S.A. Rosenberg (Eds.), Important Advances in Oncology. Lippinscott-Raven Publishers, Philadelphia, pp. 167-190.
25. Havell, E.A., Fiers, W. and North, R.J. (1988) The antitumor function of tumor necrosis factor (TNF) I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J. Exp. Med. 167, 1067-1085.
26. Schear, M.J. (1944) Chemical treatment of tumors. IX. Reactions of mice with primary subcutaneous tumors to injection of a hemorrhage-producing bacterial polysaccharide. J. Natl. Cancer Inst. 4, 461-476.
27. Nooijen, P.T.G.A., Manusama, E.R., Schalkwijk, L., Durante, N.M.C., De Waal, R.M.W., Marquet, R.L., Eggermont, A.M.M. and Ruiter, D.J. (1996) Histopathological analysis of the synergistic effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma. In press.
28. Haranaka, K., Sakurai, A. and Satomi, N. (1987) Anti-tumor activity of recombinant human tumor necrosis factor in combination with hyperthermiu, chemotherapy or immunotherapy. J. Biol. Response Modif. 6, 379-391.
29. Krosnick, J.A., Mule, J.J., McIntosh, J.K. and Rosenberg, S.A. (1989) Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res. 49, 3729-3733.
30. Manusama, E.R., Durante, N.M.C., Marquet, R.L. and Eggermont, A.M.M. (1994) Ischemia promotes the antitumor effect of tumor necrosis factor alpha (TNF-α) in isolated limb perfusion in the rat. Reg. Cancer Treat. 7, 155-159.
31. Regenass, U., Muller, M., Curschellas, E. and Matter, A. (1987) Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int J Cancer 39, 266-273.
32. Feidman, E.R., Creagan, E.T., Schaid, D.J. and Ahmann, D.L. (1992) Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma. Am. J. Clin. Oncol. 15, 256-259.
33. Kemeny, N., Childs, B., Larchian, W., Rosado, K. and Kelsen, D. (1990) A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer 66, 659-663.
34. Muggia, F., Brown, T., Goodman, P., Leichman, L., Macdonald, J. and Hersh, E. (1990) Recombinant tumor necrosis factor (rTNF) intolerance in pancreatic and gastric cancers: Southwest Oncology Group (SWOG) trials. Proc. Annu. Mett. Am. Assoc. Cancer Res. 31, A1102.
35. Rinehart, J., Balcerzak, S.P. and Hersh, E. (1990) Phase II trial of tumor necrosis factor in human sarcoma: A Southwest Oncology Group Study. Proc Annu. Meet. Am. Soc. Clin. Oncol. 9, A1229.
36. Schaadt, M., Pfreundschuh, M., Lorscheidt, G., Peters, K.M., Steinmetx, T. and Diehl, V. (1990) Phase II study of recombinant human tumor necrosis factor in colorectal carcinoma. J. Biol. Response Mod. 9, 247-250.
37. Skillings, J., Wierzbicki, R., Eisenhauer, E. et al. (1992) A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. J. Immunother. 11, 67-70.
38. Bartsch, H.H., Pfizenmaier, K., Schroeder, M. and Nagel, G.A. (1989) Intralesional application of recornbinant tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies. Eur. J. Cancer Clin. Oncol. 25, 287-291.
39. Uzermans, J.N., van der Schelling, G.P., Scheringa, M., Splinter, T.A., Marquet, R.L. and Jeekel, J. (1991) Local treatment of liver metastases with recornbinant tumour necrosis factor (rTNF): a phase one study. Neth. J. Surg. 43, 121-125.
40. Pfreundschuh, M.G., Steinmetz, H.T., Tuschen, R., Schenk, V., Diehl, V. and Schaadt, M. (1989) Phase I study of intratumoral application of recornbinant human tumor necrosis factor. Eur. J. Cancer Clin. Oncol. 25, 379-388.
41. Kahn, J.O., Kaplan, L.D., Volberding, P.A. et al. (1989) Intralesional recornbinant tumor necrosis factor-αlpha for AIDS-αssociated Kaposi's sarcoma: a randomized, double-blind trial. J. Acquir. Immune Defic. Syndr. 2, 217-223.
42. Rath, U., Kaufmann, M., Schmid, H. et al. (1991) Effect of intraperitoneal recombinant human tumor necrosis factor alpha on malignant ascites. Eur. J. Cancer 27, 121-125.
43. Liénard D., Ewalenko, Delmotte J.J., Renard N. and Lejeune F.J. (1992) High-dose recornbinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10, 50-62.
44. Eggermont, A.M.M., Schraffordt Koops, H., Lienard, D., Kroon, B.B.R., van Geel, A.N., Hoekstra, H.J. and Lejeune, F.J. (1996) Isolated limb perfusion with high dose Tumor Necrosis Factor-α in combination with interferon-γ and Melphalan for irresectalble extremity soft tissue sarcomas: a multicenter trial. J. Clin. Oncol. 14. in press.
45. Lejeune, F.J., Liénard, D., Leyvraz, S. and Mirimanoff, R.O. (1993) Regional therapy of melanoma. European Journal of Cancer 29A. 606-612.
46. Eggermont, A.M.M (1996) Treatment of melanoma intransit metastases confined to the limb. Cancer Surveys, 26, 1-15.
47. Eggermont, A.M.M., Schraffordt Koops, H., Klausner, J.M., Schlag, P.M., Kroon, B.B.R., Ben-ari, G. and Lejeune, F.J. (1996) High dose TNF-α in isolation perfusion of the limb: highly effective treatment for melanoma in transit metastases and unresectable sarcomas. In: Pinedo, Suit, Verweij (Eds.), New Developments in the Treatment of Soft Tissue Sarcoma, in press.
48. Creech, O.J., Krementz, E.T., Ryan, R.F. and Winblad, J.N. (1958) Chemotherapy of Cancer: Regional perfusion utilizing an extracorporeal circuit. Ann. Surg. 148, 612-632.
49. Asher, A., Mule, J.J., Reichert, C.M., Shiloni, E. and Rosenberg, S.A. (1987) Studies on the anti-tumor effciacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J. Immunol. 138, 963-974.
50. Benckhuijsen, C.Van Dijk, W.J. and Van't Hoff, S.C. (1982) High-flow isolation perfusion of the rat hind limb in vivo. J. Surg. Oncol. 21, 249-257.
51. Benckhuijsen, C., Kroon, B.B., Van Geel, A.N. and Wieberdink, J. (1988) Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur. J. Surg. Oncol. 14, 157-163.
52. Eggermont, A.M.M., Lienard, D., Schraffordt Koops, H., Kroon, B.B.R., Rosenkaimer, F. and Lejeune, F.J. (1994) Limb salvage by isolated perfusion of the limb with high dose tumor necrosis factor-alpha, gamma-interferon and melphalan for stage III melanoma and irresectable soft tissue sarcomas of the extremities. In: M. Freund, H. Link, R. Scmidt, and K. Welte (Eds.). Cytokines in Hemopoiesis, Oncology, and Immunology III. Springer Verlag. Berlin, pp. 609-614.
53. Liénard, D., Eggermont, A.M.M., Schraffordt Koops, H., Kroon, B.B.R. and Lejeune, F.J. (1996) Results of a randomised phase II trial on the use of TNF + Melphalan vs TNF + Melphalan + IFNγ in patients with melanoma in transit metastases confined to the limb. Eur Cytokine Netw. 7, 299.
54. Watanabe, N. Niitsu, Y., Umeno, H. et al. (1988) Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res. 48, 2179-2183.
55. Eggermont, A.M.M., Schraffordt Koops, H., Lienard, D., Lejeune, F.J. and Oukerk, M. (1994) Angiographie observations before and after high dose TNF isolated limb perfusion in patients with extremity soft tissue sarcomas. Eur. J. Surg. Oncol. 20, 323.
56. Nooijen, P.T.G.A., Manusama, E.R., Eggermont, A.M.M., Schalkwijk, L., Stavast, J., Marquet, R.L., De Waal, R.M.W. and Ruiter, D.J. (1996) Synergistic effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma. A histopathological. immunohistochemical and electronmicroscopical study. Brit. J. Cancer, in press.
57. Kort, W.J., Zondervan, P.E., Hulsman, L.O.M., van Schalkwijk, W.P., Wijma, I.M. and Westbroek, D.L. (1985) Spontaneous tumor incidence in female Brown Norway rats after lifelong diets high and low in linoleic acid. J. Natl. Cancer Inst. 74, 529-436.
58. Barendsen, G.W. and Janse, H.C. (1978) Differences in effectiveness of combined treatments with ionizing radiation and vinblastine, evaluated for experimental sarcomas and squamous cell carcinomas in rats. Int. J. Radiat. Oncol. Biol. Phys. 4, 95-102.
59. Manusama, E.R., Stavast, J., Durante, N.M.C., Marquet, R.L. and Eggermont A.M.M. (1996) Isolated limb perfusion with TNF-α and melphalan in a rat osteosarcoma model: A new anti-timour approach. Eur. J. Surg. Oncol. 22, 152-157.
60. Younger, J.S. and Algire, G.H. (1949) The effect of vascular occlusion on transplanted tumors. J. Natl. Cancer Inst. 10, 565-580.
61. Nooijen, P.T.G.A., Eggermont, A.M.M., Verbeek, M.M., Schalkwijk, L., Buurman, W.A., De Waal, R.M.W. and Ruiter, D.J. (1996) Transient induction of E-slection expression following TNF-α based isolated limb perfusion in melanoma and sarcoma patients is not tumor-specific. J. Immunother. 19, 33-44.
62. Kossodo, S., de, Moore, R., Gschmeissner, S., East, N., Upton, C. and Balkwill, F.R. (1995) Changes in endogenous cytokines, adhesion molecules and platelets during cytokin-induced tumour necrosis. Br. J. Cancer 72, 1165-1172.
63. Renard, N., Nooijen, P.T.G.A., Schalkwijk, L. et al. (1995) VWF release and platelet aggregation in human melanoma after perfusion with TNF-α. J. Pathol. 176, 279-287.
64. Prograbniak, H.W., Win, C.J., Terrill, R. et al. (1994) Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials. Ann. Thorac. Surg. 57, 1477-1483.
65. Veen van der, A.M., Manusama, E.R., Kampen van, C.A., Durante, N.M.C., Marquet, R.L. and Eggermont, A.M.M. (1994) Tumor Necrosis Factor-α (TNF-α) in isolated kidney perfusions in rats: toxicity and antitumor effects. Eur. J. Surg. Oncol. 20, 404-405.
66. Vries de, M.R., Borel Rinkes, I.H.M., Wiggers, T., Jonker, A.M., Weijers-Hille, M.J. and Eggermont, A.M.M. (1995) Hyperthermic isolated hepatic perfusion with TNF-α with and without melphalan in pigs. Eur. J. Surg. Res. 27(S1), 81.
67. Vries de, M.R., Borel Rinkes, I.H.M., Hack, C.E., Wiggers, T., Van de Velde, C.J.H., Kuppen, P.J.K. and Eggermont, A.M.M. (1995) Isolated hepatic perfusion with TNF-α: local abd systemic effects on secondary cytokine release, coagulation and fibrinolysis. Eur. J. Surg. Res. 27(S1), 109.
68. Vries de, M.R., Borel Rinkes, I.H.M., Buurman, W.A., Wiggers, T., Van de Velde, C.J.H. and Eggermont, A.M.M. (1995) Soluble TNF-α receptor induction by isolated hepatic perfusion with TNF-α and melphalan. Eur. J. Surg. Res. 27(S1), 108.
69. Fraker, D.L., Alexander, H.R. and Thorn, A.K. (1994) Use of tumor necrosis factor in isolated hepatic perfusion. Circulatory Shock 44, 45-50.
70. Huang, S.K., Lee, K.-D., Hong, K., Friend, D.S. and Papahadjopoulos, D. (1992) Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52, 5135-5143.
71. Klibanov, A.L., Murayama, K., Torchilin, V.P. and Huang, L. (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS 268, 235-237.
72. Lasic, D.D., Martin, F.J., Gabizon, A., Huang, S.K. and Papahadjopoulos, D. (1991) Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta. 1070, 187-192.
73. Woodle, M.C. and Lasic, D.D. (1992) Sterically stabilized liposomes. Biochim. Biophys. Acta 1113, 171-199.
74. Allen, T.M. (1994) Long circulating (Sterically stabilized) liposomes for targeted drug delivery. TiPS 15, 215-229.
75. Lasic, D. (1992) Liposomes. American Scientist 80, 20-31.
76. Wu, N.Z., Da, D., Rudoll, T.L., Needham, D., Whorton, A.R. and Dewhirst, M.W. (1993) Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 53, 3765-3770.
77. Kim S. (1993) Liposomes as carries of cancer chemotherapy: Current status future prospects. Drug 46, 618-638.
78. Williams, S.S., Alosco, T.R., Mayhew, E., Lasic, D.D., Martin, F.J. and Bankert, R.B. (1993) Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in Sterically stabilized liposomes. Cancer Res. 53, 3964-3967.
79. Gabizon, A., Dagan, A., Goren, D., Barenholz, Y. and Fuks, Z. (1982) Liposomes as in vivo carriers of adriamycin. Reduced cardiac uptake and preserved antitumor activity. Cancer Res. 42, 4734-4739.
80. Gabizon A., Peretz, T., Sulkes, A., Ben-Yosef, R., Be-Baruch, N., Carane, R., Biran, S. and Barenholtz, Y. (1989) Systemic administration of doxorubicin-containing liposomes in cancer patients: A phase I study. Eur. J. Cancer Clin. Oncol. 25, 1795-1803.
81. Hengge, U.R., Brockmeyer, N.H., Baumann, M., Reimann, G. and Goos, M. (1993) Liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Lancet. 342, 497.
82. Rahman, A., White, G., More, N. and Schein, P.S. (1985) Pharmacological, lexicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes. Cancer Res. 45, 796-803.
83. Hagen ten, T.L.M., Veen van der, A.H., Marquet, R.L. and Eggermont. A.M.M. (1996) Biodistribution of TNF-α encapsulated in long circulating liposomes in the BN 175 extremity soft tissue sarcoma model in Brown Norway rats. Symposium: TNF and Related Cytokines: Clinical Utility and Biology of Action and Advances in Congestive Heart Failure, Research and Therapeutics. March 10-16, Hilton Head, South Carolina.
84. Düzgünes, N., Perumal, V.K, Brunette, E.N, Gangadharam, P.R.J. and Debs, R.S. (1989) Treatment of Mycobacterium avium complex infections by free and liposome-encapsulated Tumor Necrosis Factor-alpha (Cachectin): Studies on peritoneal macrophages and the beige mouse model. In G. Lopez-Berestein, and I.J. Fidler (Eds). Liposomes in the Therapy of Infectious Disease and Cancer. UCLA, Alan R. Liss. Inc. New York, Symposium on Molecular and Cellular Biology, New Series, 89, pp. 287-294.
85. Debs, R.J., Fuchs, H.J., Philip, R., Brunette, E.N., Duzgunes, N., Shellito, J.E., Liggitt, D. and Patton, J.R. (1990) Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor a in rats. Cancer Res. 50, 375-380.
86. Saito, M., Fan, D. and Lachman, L.B. (1995) Antitumor effects of liposomal IL la and TNF-α against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice. Clin. Exp. Metastasis. 13, 249-259.
87. Gabizon, A., Isacson, R., Libson, E. et al. (1994) Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol. 33, 779-786.
88. Veen van der, A.H., ten Hagen, T.L.M., Marquet, R.L. and Eggermont, A.M.M. (1996) Treatment of solid limb tumors with liposome-encapsulated Tumor Necrosis Factor a in the rat. Proc. Am Assoc. Cancer Res. 37, 483.